Febuxostat CAS# 144060-53-7

Febuxostat, Promotion Season Now in Store and Free Sample for Testing with Factory Price

• Chemical Name: Febuxostat
• CAS No.: 144060-53-7
• Molecular Formula: C16H16N2O3S
• Molecular weight: 316.37
• Appearance: Crystalline Solid
• Sample: Available

Send Inquiry


Download Quotation

Description of Febuxostat

Febuxostat (INN; trade names Adenuric in Europe and New Zealand, Uloric in the US, Goturic in Latin America, Feburic in Japan) is a drug that inhibits xanthine oxidase, thus reducing production of uric acid in the body. It is used in the treatment of chronic gout and hyperuricemia.

Febuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998. Teijin partnered the drug with TAP Pharmaceuticals in the US and Ipsen in Europe. Ipsen obtained marketing approval for febuxostat from the European Medicines Agency in April 2008, Takeda obtained FDA approval in February 2009, and Teijin obtained approval from the Japanese “Pharmaceuticals and Medical Devices Agency” in 2011.

Basic Info of Febuxostat

Basic Info
Numbering system
Properties
Safety Info
Basic Info

Numbering system

Properties

Safety Info

What is Febuxostat?

With the progress of science and technology and the development of society, chemical products have invariably permeated our daily lives, in medicine, food, cosmetics, electronics, industry, and other areas, becoming an essential part of our lives. One such product is Febuxostat which has developed particularly rapidly in recent years. Do you know about Febuxostat?

The official answer:

Febuxostat is a new generation xanthine oxidase inhibitor developed by Teijin Japan for the clinical treatment of hyperuricemia (gout), with a completely different structure from the xanthine oxidase inhibitor drugs developed 40 years ago and is a new and highly effective non-purine xanthine oxidase selective inhibitor. Xanthine oxidase is the key enzyme that promotes uric acid production.

Uloric reduces uric acid levels in the blood of patients with hyperuricemia gout. Clinical studies have shown that this product is safe and effective. It is metabolized by the liver and is not dependent on renal excretion, so no dose reduction is required for patients with moderate to severe hepatic or renal insufficiency. In February 2009, the U.S. Food and Drug Administration (FDA) approved Uloric for the long-term treatment of gout in patients with hyperuricemia.

What’s the application of Febuxostat?

Treatment of hyperuricemia (gout); a xanthine oxidase and xanthine dehydrogenase inhibitor.

Gout is a heterogeneous group of diseases that are genetically or acquisitively caused by reduced uric acid excretion and impaired purine metabolism. The accumulation of uric acid in the body due to excessive production of uric acid and decreased clearance by the kidneys leads to the deposition of urate crystals in joints and organs.

Therefore, gout is usually treated by promoting uric acid excretion and inhibiting uric acid production, and by taking appropriate measures to improve the symptoms. The production of uric acid in the body is related to purine metabolism. In the final step of purine metabolism, hypoxanthine is produced by xanthine oxidoreductase (XOR), which further produces uric acid.

Uloric is the latest generation of non-purine selective xanthine oxidase inhibitor developed in the world, which can reduce uric acid synthesis in the body and lower uric acid concentration by acting highly selectively on this oxidase, thus effectively treating ventilation diseases.

For 30 years, allopurinol has been the only drug used clinically to inhibit uric acid production and has been widely used as a gold treatment drug for gout, achieving notable success in the treatment of anti-gout. Compared to allopurinol, Uloric has distinct advantages.

(1) Allopurinol only inhibits reduced XOR, while Uloric has significant inhibitory effects on both oxidized and reduced XOR, thus its uric acid-lowering effect is more powerful and long-lasting.

(2) Since allopurinol is a purine analog, it inevitably causes effects involving purine and other enzymatic activities of pyridine metabolism. Therefore, allopurinol therapy requires repeated high-dose administration to maintain high drug levels. This also leads to serious and even fatal adverse effects due to drug accumulation. Uloric, on the other hand, is a non-purine XOR inhibitor and therefore has a better safety profile.

Conclusion

Sincere to the customer and in good faith of quality is our forever followed motto. It’s the basement to be a human and do business. We take all responsibility for our products and service sincerely. We are a company integrating R&D, production, and sales. The design, research, and development of pharmaceutical intermediates including more than 330 kinds of pharmaceutical intermediates such as Anti-infectives, Cardiovascular and Cerebrovascular Systems, Digestive System, Santi-tumor, Nervous System, Geriatric Drugs, and Gynecological Drugs. At the same time, we have more than 4,000 factories in strategic cooperation with nearly 50,000 chemical products, so we can provide you with a one-stop purchasing service, which greatly saves customers’ procurement costs and time.

Keywords of Febuxostat

Febuxostat, 144060-53-7, buy Uloric, Uloric supplier, purchase Uloric, Uloric cost, Uloric manufacturer, order Uloric, high purity Uloric

Hot Products